Table 1.
Clinical characteristics of patients and distribution of molecular subtypes
| Characteristics | Molecular Subtypes (No. of patients) n (%) | P‐value | |||
|---|---|---|---|---|---|
| luminal A (185 cases)n (%) | luminal B(109 cases)n (%) | HER2‐enriched(81 cases)n (%) | TNBC(82 cases)n (%) | ||
| Age (years) | |||||
| ≤35 | 5 (2.7) | 7 (6.4) | 4 (4.9) | 6 (7.3) | 0.171 |
| 36–55 | 117 (63.2) | 75 (68.8) | 44 (54.3) | 52 (63.4) | |
| >55 | 63 (34.1) | 27 (24.8) | 33 (40.8) | 24 (29.3) | |
| Tumor size (cm) | |||||
| ≤2 | 112 (60.6) | 49 (44.9) | 37 (45.7) | 35 (42.7) | 0.053 |
| 2–5 | 67 (36.2) | 55 (50.5) | 40 (49.4) | 41 (50.0) | |
| >5 | 6 (3.2) | 5 (4.6) | 4 (4.9) | 6 (7.3) | |
| Lymph node metastases | |||||
| 0 | 102 (55.1) | 59 (54.1) | 34 (41.9) | 36 (43.9) | 0.261 |
| 1–3 | 46 (24.9) | 28 (25.7) | 22 (27.2) | 27 (32.9) | |
| >3 | 37 (20.0) | 22 (20.2) | 25 (30.9) | 19 (23.2) | |
| Tumor grade | |||||
| I | 20 (10.8) | 4 (3.7) | 2 (2.5) | 2 (2.4%) | 0.000 |
| II | 155 (83.8) | 80 (73.4) | 50 (61.7) | 29 (35.4) | |
| III | 10 (5.4) | 25 (22.9) | 29 (35.8) | 51 (62.2) | |
| Tumor stage | |||||
| I | 71 (38.4) | 32 (29.4) | 18 (22.2) | 18 (21.9) | 0.027 |
| II | 73 (39.4) | 53 (48.6) | 36 (44.5) | 45 (54.9) | |
| III | 41 (22.2) | 24 (22.0) | 27 (33.3) | 19 (23.2) | |
| IV | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
TNBC, triple‐negative breast cancer.